BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...– Neuregulin 4PPP1 – Protein phosphatase 1PPP1R1A – Protein phosphatase...
BioCentury | Oct 13, 2020
Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

...and CEO Mark Burk, is developing lasso peptides for cancer, autoimmunity, pain and inflammation. TargetsPP2A – Protein phosphatase...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting the PP2A-STRN3 interaction to treat gastric cancer

...peptide reduced tumor size.TARGET/MARKER/PATHWAY: Protein phosphatase 2 (PP2A); protein phosphatase...
...Shanghai, Chinaemail: zczhou@sibcb.ac.cn Claire Quang Chinese Academy of Sciences Fudan University Protein phosphatase...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

...chemokine receptor 7 EGFR (ErbB1; HER1) - Epidermal growth factor receptor p53 (TP53) PP1 - Protein phosphatase...
BioCentury | Sep 19, 2019
Distillery Therapeutics

Blocking the NAD+ biosynthesis enzyme NamPRT for PPM1D-mutant tumors

...has a NamPRT inhibitor, OT-82, in preclinical testing for leukemia, lymphoma and multiple myeloma. TARGET/MARKER/PATHWAY: Protein phosphatase...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Autoimmune disease

...depression. Neuro Pharmalogics Inc. has the PP2A inhibitor NP-101 in preclinical testing for migraine. TARGET/MARKER/PATHWAY: Protein phosphatase...
...Lu, Zhejiang University School of Medicine, Hangzhou, China email: lu_linrong@zju.edu.cn Claire Quang Nanjing University Zhejiang University School of Medicine Protein phosphatase...
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

...AD, PSP and other tauopathies University of Texas Health Science Center Distillery Therapeutics Huntington’s disease Protein phosphatase...
BioCentury | Sep 7, 2018
Financial News

Qiming, Hillhouse lead Jacobio's $55M series C

...to treat advanced solid tumors. The company is also developing JAB-3000, an anti-tumor therapy against protein phosphatase...
BioCentury | Sep 6, 2018
Finance

Jacobio’s ladder

...tumors. Its target is undisclosed. The company is also developing preclinical compound JAB-3000, which targets protein phosphatase...
BioCentury | Aug 31, 2018
Financial News

Qiming, Hillhouse lead Jacobio's $55M series C

...to treat advanced solid tumors. The company is also developing JAB-3000, an anti-tumor therapy against protein phosphatase...
Items per page:
1 - 10 of 100